<?xml version='1.0' encoding='utf-8'?>
<document id="23085095"><sentence text="The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone."><entity charOffset="29-38" id="DDI-PubMed.23085095.s1.e0" text="aconitine" /><entity charOffset="242-251" id="DDI-PubMed.23085095.s1.e1" text="buspirone" /><pair ddi="false" e1="DDI-PubMed.23085095.s1.e0" e2="DDI-PubMed.23085095.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23085095.s1.e0" e2="DDI-PubMed.23085095.s1.e1" /></sentence><sentence text="Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries" /><sentence text=" The herbs are always used with drugs such as paclitaxel"><entity charOffset="46-56" id="DDI-PubMed.23085095.s3.e0" text="paclitaxel" /></sentence><sentence text=" Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum roots"><entity charOffset="1-10" id="DDI-PubMed.23085095.s4.e0" text="Aconitine" /><entity charOffset="12-14" id="DDI-PubMed.23085095.s4.e1" text="AC" /><entity charOffset="56-65" id="DDI-PubMed.23085095.s4.e2" text="alkaloids" /><pair ddi="false" e1="DDI-PubMed.23085095.s4.e0" e2="DDI-PubMed.23085095.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23085095.s4.e0" e2="DDI-PubMed.23085095.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23085095.s4.e0" e2="DDI-PubMed.23085095.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23085095.s4.e1" e2="DDI-PubMed.23085095.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23085095.s4.e1" e2="DDI-PubMed.23085095.s4.e2" /></sentence><sentence text=" AC is metabolized by cytochrome P450 (CYP) 3A"><entity charOffset="1-9" id="DDI-PubMed.23085095.s5.e0" text="AC" /></sentence><sentence text=" However, whether AC inhibits/induces CYP3A, which causes drug-drug interaction (DDI) is unclear"><entity charOffset="18-19" id="DDI-PubMed.23085095.s6.e0" text="AC" /></sentence><sentence text=" Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats"><entity charOffset="113-122" id="DDI-PubMed.23085095.s7.e0" text="buspirone" /><entity charOffset="49-57" id="DDI-PubMed.23085095.s7.e1" text="AC" /><pair ddi="false" e1="DDI-PubMed.23085095.s7.e1" e2="DDI-PubMed.23085095.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23085095.s7.e1" e2="DDI-PubMed.23085095.s7.e0" /></sentence><sentence text=" The effects of oral AC on pharmacokinetics of buspirone were evaluated"><entity charOffset="47-56" id="DDI-PubMed.23085095.s8.e0" text="buspirone" /><entity charOffset="21-29" id="DDI-PubMed.23085095.s8.e1" text="AC" /><pair ddi="false" e1="DDI-PubMed.23085095.s8.e1" e2="DDI-PubMed.23085095.s8.e1" /><pair ddi="false" e1="DDI-PubMed.23085095.s8.e1" e2="DDI-PubMed.23085095.s8.e0" /></sentence><sentence text=" CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot"><entity charOffset="117-126" id="DDI-PubMed.23085095.s9.e0" text="buspirone" /><entity charOffset="80-88" id="DDI-PubMed.23085095.s9.e1" text="AC" /><pair ddi="false" e1="DDI-PubMed.23085095.s9.e1" e2="DDI-PubMed.23085095.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23085095.s9.e1" e2="DDI-PubMed.23085095.s9.e0" /></sentence><sentence text=" Buspirone and its major metabolites 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone were determined using a newly validated UPLC-MS/MS method"><entity charOffset="1-10" id="DDI-PubMed.23085095.s10.e0" text="Buspirone" /><entity charOffset="37-64" id="DDI-PubMed.23085095.s10.e1" text="1-(2-pyrimidinyl)piperazine" /><entity charOffset="69-88" id="DDI-PubMed.23085095.s10.e2" text="6'-hydroxybuspirone" /><pair ddi="false" e1="DDI-PubMed.23085095.s10.e0" e2="DDI-PubMed.23085095.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23085095.s10.e0" e2="DDI-PubMed.23085095.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23085095.s10.e0" e2="DDI-PubMed.23085095.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23085095.s10.e1" e2="DDI-PubMed.23085095.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23085095.s10.e1" e2="DDI-PubMed.23085095.s10.e2" /></sentence><sentence text=" Single dose and 7-day AC administration at 0"><entity charOffset="23-41" id="DDI-PubMed.23085095.s11.e0" text="AC" /></sentence><sentence text="125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone"><entity charOffset="77-104" id="DDI-PubMed.23085095.s12.e0" text="1-(2-pyrimidinyl)piperazine" /><entity charOffset="109-128" id="DDI-PubMed.23085095.s12.e1" text="6'-hydroxybuspirone" /><pair ddi="false" e1="DDI-PubMed.23085095.s12.e0" e2="DDI-PubMed.23085095.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23085095.s12.e0" e2="DDI-PubMed.23085095.s12.e1" /></sentence><sentence text=" CYP3A activity and protein levels in liver microsomes were also not affected by 7-day AC pretreatment at 0"><entity charOffset="87-105" id="DDI-PubMed.23085095.s13.e0" text="AC" /></sentence><sentence text="125mg/kg" /><sentence text=" Therefore, AC neither inhibits nor induces CYP3A in rats, indicating AC does not cause CYP3A-related DDI in the liver"><entity charOffset="12-13" id="DDI-PubMed.23085095.s15.e0" text="AC" /><entity charOffset="70-71" id="DDI-PubMed.23085095.s15.e1" text="AC" /><pair ddi="false" e1="DDI-PubMed.23085095.s15.e0" e2="DDI-PubMed.23085095.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23085095.s15.e0" e2="DDI-PubMed.23085095.s15.e1" /></sentence><sentence text="" /></document>